Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 21.43
FVD's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 21.43 )
Ranked among companies with meaningful PE Ratio only.
FVD' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.86
Current: 21.43
0
21.86
PE Ratio without NRI 21.43
FVD's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 21.43 )
Ranked among companies with meaningful PE Ratio without NRI only.
FVD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.86
Current: 21.43
0
21.86
PB Ratio 2.69
FVD's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.69 )
Ranked among companies with meaningful PB Ratio only.
FVD' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.78
Current: 2.69
0
2.78

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.96
FVD's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 1.96 )
Ranked among companies with meaningful Dividend Yield % only.
FVD' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.16
Current: 1.96
0
2.16
5-Year Yield-on-Cost % 1.96
FVD's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 1.96 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
FVD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.16
Current: 1.96
0
2.16

More Statistics

Short Percentage of Float0.00%
52-Week Range $25.38 - 29.45
Shares Outstanding (Mil)99,999,999.99
» More Articles for FVD

Headlines

Articles On GuruFocus.com
Ray Dalio Releases Article 'Populism: The Phenomenon' Mar 22 2017 
GMO: The Deep Causes of Secular Stagnation and the Rise of Populism Mar 22 2017 
Seth Klarman Dividend Stocks in Focus: ChipMOS Technologies Mar 22 2017 
Seth Klarman Dividend Stocks in Focus: Colony NorthStar Mar 22 2017 
GAMCO Investors Touts Gabelli Food of All Nations NextShares Mar 22 2017 
A Bad View From the 'Bleacher' Seats Mar 22 2017 
Ariel Funds: Bank Stocks Are Overvalued Mar 22 2017 
AngloGold Ashanti Is Going Ex-Dividend Mar 22 2017 
Roper Technologies Looks Promising Mar 22 2017 
Galapagos Begins Cystis Fibrosis Treatment Study Mar 22 2017 

More From Other Websites
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds Mar 22 2017
What Will Drive AstraZeneca’s Oncology Revenues in 2017? Mar 22 2017
AstraZeneca’s New Products May Offer 2017 Growth Opportunities Mar 01 2017
Growth of AstraZeneca’s Oncology Segment in 2016 Mar 01 2017
Teva Is Expected to See a Fall in Its Profit Margins in 2017 Feb 23 2017
A Dividend ETF On The Rise Feb 22 2017
These Prescription Products Matter to Sanofi’s Growth Feb 20 2017
Novartis’s Valuation after the 4Q16 Results Feb 03 2017
Inside Novartis’s Generics Performance in 4Q16 Feb 02 2017
Analysts Expect Negative Growth for Novartis in 4Q16 Jan 23 2017
How Did Novartis’s Innovative Medicines Segment Perform? Jan 17 2017
AstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016 Jan 02 2017
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds Dec 20 2016
Teva’s Research Pipeline to Culminate in Many New Drug Launches? Nov 24 2016
The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug Nov 22 2016
Teva Pharmaceutical Expects Mid-Single-Digit Growth for Generics Nov 21 2016
Performance of Novartis’s Innovative Medicines Segment in 3Q16 Nov 17 2016
Changes in Novartis’s Valuation for 3Q16 Nov 16 2016
Bernstein: Excess Risk Aversion Has Made Investors ‘Wallflowers’ Nov 16 2016
Inside AstraZeneca’s Oncology Segment Growth in 3Q15 Nov 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK